Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xb3 TM-001 in Brain Cancer

Bioasis Technologies and testing services provider BioAgilytix will partner on the development and validation of bioanalytical methods to support and advance the xB3 -001 program, Bioasis’ lead candidate to treat HER2+ brain cancer.

Click for full article
Share This

Other Podcasts

Molecular Moments Episode 2 Banner
Welcome to episode one of the Molecular Moments podcast! On this first episode, Dr. Chad Briscoe is joined by his guest, Ph.D scientist, Dr. Jim McNally, and they get down to business as the two explore the various nuances in the outstanding work of McNally, how his career in bioanalysis became personal in an unexpected…
Molecular Moments Episode 2 Banner
In today’s episode, Dr. Chad Briscoe sits down with guest scientist and biomarker expert, Dr. Marianne Fjording (Scientific Officer, BioAgilytix). Marianne and Chad discuss her expertise in biomarkers and EU bioanalysis- including how Denmark became a scientific hub and what fit-for-purpose really means. They also dive into Marianne’s jump from pharma to CRO, a family…